Table 1.
Characteristics of study population by sex and age
| P values for sex and age | Sex | Age | |||||
|---|---|---|---|---|---|---|---|
| F | M | 0 TO 2 years | 3 TO 4 years | 5 TO 9 years | 10 TO 14 years | ||
| Age (months) | Mean (SD) | 51 (39) | 52 (42) | 13 (6) | 42 (11) | 85 (17) | 138 (14) |
| CD4 (cells/mm3) p*: 0.014; <0.0001 | Mean (SD) | 708 (623) | 606(512) | 801(607) | 760 (541) | 477(494) | 268(385) |
| Missing | 17 | 12 | 16 | 4 | 7 | 2 | |
| Baseline who stage p: 0.944; 0.537 | I: N(%) | 30 (9.5) | 37(10.9) | 30 (12.9) | 19(10.1) | 16 (9.1) | 2 (3.5) |
| II : N(%) | 84(26.7) | 77(22.8) | 54(23.3) | 50(26.6) | 40 (22.9) | 17 (29.8) | |
| III: N(%) | 191(61) | 217(64.2) | 142 (61.2) | 115(61.2) | 114 (65.1) | 37 (64.9) | |
| IV : N(%) | 9 (2.9) | 7(2.1) | 6(2.6) | 4(2.1) | 5 (2.9) | 1(1.8) | |
| Missing | 4 | 4 | 4 | 1 | 3 | 0 | |
| Outcome pb: 0.325; 0.003 | aCOT(N,%) | 207 (65.2) | 217 (63.5) | 141(59.7) | 130(68.8) | 115(64.6) | 38(66.7) |
| D(N,%) | 28 (8.8) | 38(11.1) | 37(15,7) | 12(6.3) | 11(6.2) | 6(10.5) | |
| LTF(N,%) | 53(16.6) | 56(16.4) | 43(18.2) | 27(14.3) | 32(18.0) | 7(12.3) | |
| STOP(N,%) | 2(0.6) | 6(1.8) | 4(1.7) | 1(0.5) | 3(1.7) | 0(0.0) | |
| TO(N,%) | 28(8.8) | 25(7.3) | 11(4.7) | 19(10.1) | 17(9.6) | 6(10.5) | |
| Follow up time (months) p: 0.484; 0.001 | Mean(SD) | 46(25) | 44(25) | 40(24) | 49(24) | 47(26) | 45(25) |
| Baseline HB (g/dl) p: 0.463; 0.327 | Mean(SD) | 10.44(3.91) | 10.19(3.86) | 10.29(4.01) | 10.75(4.88) | 9.98(2.46) | 9.90(2.89) |
| Missing | 71 | 83 | 65 | 34 | 43 | 12 | |
| Year of art initiation p: 0.848; 0.033 | 2005 (N,%) | 32(10.1) | 36(10.5) | 17(25) | 26(38.2) | 22(32.4) | 3(4.4) |
| 2006(N,%) | 77(24.2) | 82(24.0) | 47(29.6) | 52(32.7) | 43(27) | 17(10.7) | |
| 2007(N,%) | 50(15.7) | 45(13.2) | 26(27.4) | 27(28.4) | 32(33.7) | 10(10.5) | |
| 2008(N,%) | 62(19.5) | 80(23.4) | 67(47.2) | 33(23.2) | 35(24.6) | 7(4.9) | |
| 2009 (N,%) | 40(12.6) | 44(12.9) | 38(45.2) | 26(31) | 13(15.5) | 7(8.3) | |
| 2010(N,%) | 28(9.1) | 27(7.9) | 24(43.6) | 10(18.2) | 14(25.5) | 7(12.7) | |
| 2011 (N,%) | 29(9.1) | 28(8.2) | 17(29.8) | 15(26.3) | 19(33.3) | 6(10.5) | |
*P values based on log-transformed CD4 values
a COT Currently on treatment, D Death, LTF Lost to Follow up, STOP Stopped treatment electively, TO Transferred out to another facility
bOnly Mortality was considered as outcome of interest in the ANOVA analysis